Primary Membranous Nephropathy - what do we know today?
DOI:
https://doi.org/10.12775/QS.2023.13.01.007Keywords
primary membranous nephropathy, nephrotic syndrome, chronic kidney diseaseAbstract
Introduction: Primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome in adults, characterized by the deposition of immune complexes in the glomerular basement membrane.
Aim of this study: evaluate the features of PMN such as incidence, pathology, clinical features and assess the effectiveness of immunosuppressive therapy.
Materials and Methods: The review was based on articles found in PubMed database, using keyword „primary membranous nephropathy” with appropriate sufixes.
Results: PMN is a challenging disease that requires a multidisciplinary approach to diagnosis and management. Laboratory tests, including assessment of autoantibodies and complement levels, are essential for the diagnosis of PMN. Immunosuppressive therapy can be effective in inducing remission in a significant proportion of patients.
Conclusions: Further research is needed to optimize the duration and intensity of immunosuppressive therapy, and to evaluate the role of newer therapies such as rituximab and belimumab.
References
D. C. Cattran and P. E. Brenchley, “Membranous nephropathy: integrating basic science into improved clinical management,” Kidney Int., vol. 91, no. 3, pp. 566–574, Mar. 2017, doi: 10.1016/J.KINT.2016.09.048.
A. S. Bomback and F. C. Fervenza, “Membranous Nephropathy: Approaches to Treatment,” Am. J. Nephrol., vol. 47 Suppl 1, pp. 30–42, Jun. 2018, doi: 10.1159/000481635.
W. G. Couser, “Primary membranous nephropathy,” Clin. J. Am. Soc. Nephrol., vol. 12, no. 6, pp. 983–997, 2017, doi: 10.2215/CJN.11761116.
M. Infantino, “Editorial: Primary membranous nephropathy,” Front. Immunol., vol. 13, Dec. 2022, doi: 10.3389/fimmu.2022.1102036.
“Orphanet: Primary membranous glomerulonephritis.”
R. Wang et al., “Long-term renal survival and related risk factors for primary membranous nephropathy in Chinese children: a retrospective analysis of 217 cases,” J. Nephrol., vol. 34, no. 2, pp. 589–596, Apr. 2021, doi: 10.1007/S40620-020-00816-Y/FIGURES/3.
H. C. Stanescu et al., “Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy,” N. Engl. J. Med., vol. 364, no. 7, pp. 616–626, Feb. 2011, doi: 10.1056/NEJMOA1009742.
Z. Cui et al., “MHC Class II risk alleles and amino acid residues in idiopathic membranous nephropathy,” J. Am. Soc. Nephrol., vol. 28, no. 5, pp. 1651–1664, May 2017, doi: 10.1681/ASN.2016020114/-/DCSUPPLEMENTAL.
N. M. Tomas et al., “Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy,” N. Engl. J. Med., vol. 371, no. 24, pp. 2277–2287, Dec. 2014, doi: 10.1056/NEJMOA1409354/SUPPL_FILE/NEJMOA1409354_DISCLOSURES.PDF.
H. H. L. Wu et al., “Risk factors of venous thromboembolism in anti-PLA2R-positive and negative primary membranous nephropathy,” Clin. Kidney J., vol. 15, no. 8, p. 1636, Aug. 2022, doi: 10.1093/CKJ/SFAC052.
P. Ronco and H. Debiec, “Pathophysiological advances in membranous nephropathy: time for a shift in patient’s care,” Lancet (London, England), vol. 385, no. 9981, pp. 1983–1992, May 2015, doi: 10.1016/S0140-6736(15)60731-0.
I. Smarz-Widelska, D. Chojęta, and M. M. Kozioł, “The Role of Anti-PLA2R and Anti-THSD7A Antibodies in the Pathogenesis and Diagnostics of Primary Membranous Nephropathy: A Review of Current Knowledge for Clinical Practice,” Int. J. Environ. Res. Public Heal. 2022, Vol. 19, Page 5301, vol. 19, no. 9, p. 5301, Apr. 2022, doi: 10.3390/IJERPH19095301.
Y. Gu, H. Xu, and D. Tang, “Mechanisms of Primary Membranous Nephropathy,” Biomol. 2021, Vol. 11, Page 513, vol. 11, no. 4, p. 513, Mar. 2021, doi: 10.3390/BIOM11040513.
X. Li et al., “Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy,” Med. Sci. Monit., vol. 22, pp. 1630–1636, May 2016, doi: 10.12659/MSM.896090.
H. Z. Qin et al., “Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy,” J. Am. Soc. Nephrol., vol. 27, no. 10, pp. 3195–3203, 2016, doi: 10.1681/ASN.2015080953.
J. Herwig et al., “Thrombospondin type 1 domain–containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes,” J. Am. Soc. Nephrol., vol. 30, no. 5, pp. 824–839, May 2019, doi: 10.1681/ASN.2018090941/-/DCSUPPLEMENTAL.
C. Zaghrini et al., “Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy,” Kidney Int., vol. 95, no. 3, pp. 666–679, Mar. 2019, doi: 10.1016/J.KINT.2018.10.024.
Y. Liu et al., “Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy,” Glob. Challenges, vol. 4, no. 11, p. 1900099, Nov. 2020, doi: 10.1002/GCH2.201900099.
H. Debiec et al., “Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies,” Lancet, vol. 364, no. 9441, pp. 1252–1259, Oct. 2004, doi: 10.1016/S0140-6736(04)17142-0.
M. Vivarelli et al., “Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies,” Kidney Int., vol. 87, no. 3, pp. 602–609, Mar. 2015, doi: 10.1038/KI.2014.381.
M. Prunotto et al., “Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2,” J. Am. Soc. Nephrol., vol. 21, no. 3, p. 507, Mar. 2010, doi: 10.1681/ASN.2008121259.
S. Sethi et al., “Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy,” Kidney Int., vol. 97, no. 1, pp. 163–174, Jan. 2020, doi: 10.1016/J.KINT.2019.09.014.
D. Cattran and P. Brenchley, “Membranous nephropathy: thinking through the therapeutic options,” Nephrol. Dial. Transplant, vol. 32, no. suppl_1, pp. I22–I29, Jan. 2017, doi: 10.1093/NDT/GFW404.
M. A. Hladunewich, S. Troyanov, J. Calafati, and D. C. Cattran, “The Natural History of the Non-Nephrotic Membranous Nephropathy Patient,” Clin. J. Am. Soc. Nephrol., vol. 4, no. 9, p. 1417, 2009, doi: 10.2215/CJN.01330209.
M. J. Guerry, P. Vanhille, P. Ronco, and H. Debiec, “Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy,” Kidney Int., vol. 89, no. 6, p. 1399, 2016, doi: 10.1016/J.KINT.2015.11.032.
H. Trujillo and M. Praga, “Membranous nephropathy: an update,” Port. J. Nephrol. Hypertens., vol. 33, no. 1, Apr. 2019, doi: 10.32932/PJNH.2019.04.006.
K. C. Keri, S. Blumenthal, V. Kulkarni, L. Beck, and T. Chongkrairatanakul, “Primary membranous nephropathy: comprehensive review and historical perspective,” Postgrad. Med. J., vol. 95, no. 1119, pp. 23–31, Jan. 2019, doi: 10.1136/POSTGRADMEDJ-2018-135729.
N. Leeaphorn, P. Kue-A-Pai, N. Thamcharoen, P. Ungprasert, M. B. Stokes, and E. L. Knight, “Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies,” Am. J. Nephrol., vol. 40, no. 1, pp. 29–35, 2014, doi: 10.1159/000364782.
P. R. Stahl, E. Hoxha, T. Wiech, C. Schröder, R. Simon, and R. A. K. Stahl, “THSD7A expression in human cancer,” Genes. Chromosomes Cancer, vol. 56, no. 4, pp. 314–327, Apr. 2017, doi: 10.1002/GCC.22440.
E. Hoxha et al., “A Mechanism for Cancer-Associated Membranous Nephropathy,” N. Engl. J. Med., vol. 374, no. 20, pp. 1995–1996, May 2016, doi: 10.1056/NEJMC1511702.
M. Haas, “IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies,” Am. J. Kidney Dis., vol. 23, no. 3, pp. 358–364, 1994, doi: 10.1016/S0272-6386(12)80997-8.
J. M. Francis, L. H. Beck, and D. J. Salant, “Membranous Nephropathy: A Journey From Bench to Bedside,” Am. J. Kidney Dis., vol. 68, no. 1, p. 138, Jul. 2016, doi: 10.1053/J.AJKD.2016.01.030.
A. S. De Vriese, R. J. Glassock, K. A. Nath, S. Sethi, and F. C. Fervenza, “A Proposal for a Serology-Based Approach to Membranous Nephropathy,” J. Am. Soc. Nephrol. JASN, vol. 28, no. 2, pp. 421–430, Feb. 2017, doi: 10.1681/ASN.2016070776.
“KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases,” Kidney Int., vol. 100, no. 4S, pp. S1–S276, Oct. 2021, doi: 10.1016/j.kint.2021.05.021.
R. Saran et al., “A Randomized Crossover Trial of Dietary Sodium Restriction in Stage 3-4 CKD,” Clin. J. Am. Soc. Nephrol. CJASN, vol. 12, no. 3, pp. 399–407, Mar. 2017, doi: 10.2215/CJN.01120216.
K. T. Mills et al., “Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease,” JAMA, vol. 315, no. 20, pp. 2200–2210, May 2016, doi: 10.1001/jama.2016.4447.
M. O’Donnell et al., “Urinary sodium and potassium excretion, mortality, and cardiovascular events,” N. Engl. J. Med., vol. 371, no. 7, pp. 612–623, Aug. 2014, doi: 10.1056/NEJMoa1311889.
J. Bernhard, B. Beaufrère, M. Laville, and D. Fouque, “Adaptive response to a low-protein diet in predialysis chronic renal failure patients,” J. Am. Soc. Nephrol. JASN, vol. 12, no. 6, pp. 1249–1254, Jun. 2001, doi: 10.1681/ASN.V1261249.
P. A. Sarafidis, N. Khosla, and G. L. Bakris, “Antihypertensive therapy in the presence of proteinuria,” Am. J. Kidney Dis. Off. J. Natl. Kidney Found., vol. 49, no. 1, pp. 12–26, Jan. 2007, doi: 10.1053/j.ajkd.2006.10.014.
H. T. Yu, “Progression of chronic renal failure,” Arch. Intern. Med., vol. 163, no. 12, pp. 1417–1429, Jun. 2003, doi: 10.1001/archinte.163.12.1417.
T. Lee et al., “Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy,” Kidney Int., vol. 85, no. 6, pp. 1412–1420, Jun. 2014, doi: 10.1038/ki.2013.476.
J. Rojas-Rivera, F. C. Fervenza, and A. Ortiz, “Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy,” Drugs, vol. 82, no. 2, pp. 109–132, Feb. 2022, doi: 10.1007/s40265-021-01656-1.
C. Ponticelli et al., “A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy,” N. Engl. J. Med., vol. 320, no. 1, pp. 8–13, Jan. 1989, doi: 10.1056/NEJM198901053200102.
J. A. J. G. van den Brand et al., “Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy,” J. Am. Soc. Nephrol. JASN, vol. 28, no. 9, pp. 2729–2737, Sep. 2017, doi: 10.1681/ASN.2016091022.
D. Williams and L. Haragsim, “Calcineurin nephrotoxicity,” Adv. Chronic Kidney Dis., vol. 13, no. 1, pp. 47–55, Jan. 2006, doi: 10.1053/j.ackd.2005.11.001.
Y. Guo et al., “Rituximab in patients with membranous nephropathy and kidney insufficiency,” Front. Pharmacol., vol. 13, p. 1002117, Oct. 2022, doi: 10.3389/fphar.2022.1002117.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marcin Wais, Konrad Warchoł, Adam Jasiura, Aleksandra Wójcik, Kamila Giżewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 501
Number of citations: 0
